# Evaluation of Safety and Efficacy of AVE5530 as add-on to Ongoing Statins in Patients With Primary Hypercholesterolemia

> **NCT00729027** · PHASE3 · TERMINATED · sponsor: **Sanofi** · enrollment: 1015 (actual)

## Conditions studied

- Hypercholesterolemia

## Interventions

- **DRUG:** 25 mg/day AVE5530
- **DRUG:** 50 mg/day AVE5530
- **DRUG:** placebo

## Key facts

- **NCT ID:** NCT00729027
- **Lead sponsor:** Sanofi
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2008-07
- **Primary completion:** 2009-06
- **Final completion:** 2009-06
- **Target enrollment:** 1015 (ACTUAL)
- **Why stopped:** AVE5530 in hypercholesterolemia was stopped due to insufficient efficacy
- **Last updated:** 2016-05-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00729027

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00729027, "Evaluation of Safety and Efficacy of AVE5530 as add-on to Ongoing Statins in Patients With Primary Hypercholesterolemia". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00729027. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*